A common hurdle for many drug delivery applications is getting the desired compounds to the targeted cells or receptors. Additional barriers of achieving the therapeutic drug concentration and necessary drug diffusion are also present even after successful targeted delivery.
Researchers in Dr. Karl Deisseroth's laboratory at Stanford University have developed a novel suite of genetically-encodable, optically-activated modulators of second messengers (such as cAMP and IP3).
Researchers in Dr. Karl Deisseroth's laboratory have developed a novel method to rapidly identify neurophysiological measures associated with psychiatric disease and then use those correlates to screen for therapeutics.
Stanford researchers at the Airan Lab have developed a new method for robust and spatiotemporally precise non-invasive neuromodulation that could transform both basic and clinical neuroscience.